Last reviewed · How we verify
NCT04041778: USURPAF
'Understanding the Electrophysiological Substrate Underlying Persistent Atrial Fibrillation Study II (USURP AF- Study II)'
trial testing Catheter ablation in Atrial Fibrillation Mechanisms in 17 participants. Completed in 30 September 2024.
30 September 2024
Quick facts
| Lead sponsor | University of Leicester |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 17 |
| Start date | 25 July 2019 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Catheter ablation
Conditions studied
- Atrial Fibrillation Mechanisms — all drugs for Atrial Fibrillation Mechanisms →
- Persistent Atrial Fibrillation — all drugs for Persistent Atrial Fibrillation →
- Substrate Ablation — all drugs for Substrate Ablation →
- Pulmonary Vein Isolation — all drugs for Pulmonary Vein Isolation →
Sponsor
University of Leicester
Who can join
18 and older, any sex, with Atrial Fibrillation Mechanisms or Persistent Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Atrial fibrillation (AF) is the most common type of chronic heart rhythm disease worldwide, with significant associated co-morbidities. Although there have been advances in understanding the mechanisms of AF, the underlying cause of AF and factors which perpetuate it remain incompletely understood. This is particularly the case for persistent AF (persAF). Drug treatments for persAF have a role but can have undesirable side effects with relatively limited efficacy. Furthermore, current invasive therapies for persAF remain suboptimal, requiring significant resources, and with potentially serious complications for patients. Catheter ablation is an effective treatment for paroxysmal AF. For persistent AF (persAF), however, catheter ablation does not provide similar results. This is because there remains a poor understanding of the electrophysiological mechanisms driving persAF. Part of this study aims to further explore the specific locations that represent important substrates which would guide more effective catheter ablation. There have been several different ablation approaches explored in the past (see below), however, these did not improve the outcome post procedure compared with pulmonary vein isolation alone. A pilot study has already been carried out and I aim to expand this further with a larger cohort of patients (10-20) over 2 years. In this study the investigators want to explore whether stable high dominant frequency (HDF) sites (with a high organisation index) act as potential drivers of Atrial Fibrillation. Thus, targeting these sites may results in prolongation of the cycle length and thus possible termination of the arrhythmia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04041778
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Catheter ablation
Trials testing the same drug.
- NCT07445334 — Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes · NA · not yet recruiting
- NCT06632925 — Utility of Analyzing Atrial Signal Electrograms in Patients with Atrial Fibrillation Using Next-Generation Ensite X Soft · active not recruiting
- NCT06556485 — Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure · NA · recruiting
- NCT06560047 — Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure · NA · recruiting
- NCT06182566 — Hybrid Persistent Atrial Fibrillation Ablation in Heart Failure · NA · withdrawn
Other recruiting trials for Atrial Fibrillation Mechanisms
Currently open trials in the same condition.
- NCT07047235 — Substrate Remodelling and Targeted Ablation in AF · NA · recruiting
Other University of Leicester trials
Trials by the same sponsor.
- NCT07389785 — Age Related Chromatin Remodelling as a Therapeutic Target for Organ Protection in Cardiac Surgery · active not recruiting
- NCT07014579 — Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People · not yet recruiting
- NCT06955663 — Exercise Support and Rehabilitation for Patients After Spontaneous Coronary Artery Dissection · NA · recruiting
- NCT06629675 — Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD · NA · recruiting
- NCT06844656 — Understanding the Increased Risk of Atrial Fibrillation in Athletes: a Case-control Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04041778 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Leicester
- Last refreshed: 1 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04041778.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing